Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H11NO4S2 |
| Molecular Weight | 249.307 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CSCC(=O)NC1CCSC1=O
InChI
InChIKey=QGFORSXNKQLDNO-UHFFFAOYSA-N
InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)
| Molecular Formula | C8H11NO4S2 |
| Molecular Weight | 249.307 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: http://www.erdosteine.net/Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/18046899, https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf
Sources: http://www.erdosteine.net/
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/18046899, https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf
Erdosteine is an antioxidant compound developed by Edmond Pharma and approved in Europe for the treatment of chronic bronchitis and COPD. Erdosteine has two thiol groups and is believed to act as a free radicals scavenger (through the formation of the active metabolite I, N-thiodiglycolylhomocysteine). Also the drug effect may be due to the inhibition of the activity of elastase enzyme and its interaction with mucosa. The drug got Orphan Drug designation by FDA for the treatment of bronchiectasis.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0070254 |
|||
Target ID: P08246 Gene ID: 1991.0 Gene Symbol: ELANE Target Organism: Homo sapiens (Human) |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ERDOTIN Approved UseMucolytic agent in acute and chronic respiratory diseases. |
|||
| Primary | ERDOTIN Approved UseMucolytic agent in acute and chronic respiratory diseases. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.419 μg/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.594 μg/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.34 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.15 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.45 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.17 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.492 μg × h/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.523 μg × h/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.55 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.32 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.23 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.478 h |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.603 h |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.36 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.68 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.49 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils. | 2002 |
|
| The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. | 2002 |
|
| Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats. | 2003 Apr |
|
| Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. | 2003 Feb |
|
| Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. | 2003 Oct |
|
| Sensitive determination of erdosteine in human plasma by use of automated 96-well solid-phase extraction and LC-MS/MS. | 2004 Feb 18 |
|
| Inhibitory effects of metabolite I of erdosteine on the generation of nitric oxide and peroxynitrite chemiluminescence by human neutrophils. | 2004 Jul |
|
| Erdosteine improves oxidative damage in a rat model of renal ischemia-reperfusion injury. | 2004 Jul-Aug |
|
| A combination of budesonide and the SH-metabolite I of erdosteine acts synergistically in reducing chemiluminescence during human neutrophil respiratory burst. | 2005 Jun |
|
| Role of mucolytics in the management of COPD. | 2006 |
|
| Pharmacological treatment of chronic obstructive pulmonary disease. | 2006 |
|
| Regulation of sepsis-induced apoptosis of pulmonary cells by posttreatment of erdosteine and N-aceylcysteine. | 2006 Dec 7 |
|
| Comparison of the effects of erdosteine and N-acetylcysteine on apoptosis regulation in endotoxin-induced acute lung injury. | 2006 Jul-Aug |
|
| Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. | 2007 Dec |
|
| Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction. | 2007 Mar |
|
| The effects of erdosteine, N-acetylcysteine and vitamin E on nicotine-induced apoptosis of cardiac cells. | 2007 May-Jun |
|
| Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. | 2007 Sep |
|
| Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. | 2008 |
|
| Antioxidant effect of sulphurous thermal water on human neutrophil bursts: chemiluminescence evaluation. | 2008 |
|
| The effects of erdosteine on lung injury induced by the ischemia-reperfusion of the hind-limbs in rats. | 2008 Apr |
|
| Antioxidant therapeutic advances in COPD. | 2008 Dec |
|
| Renoprotective effect of erdosteine in rats against gentamicin nephrotoxicity: a comparison of 99mTc-DMSA uptake with biochemical studies. | 2008 Jan |
|
| Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. | 2008 Oct |
|
| Erdosteine modulates radiocontrast-induced hepatotoxicity in rat. | 2009 Apr |
|
| Raft of results energizes researchers. | 2009 Sep-Oct |
|
| Free radical scavenging activity of erdosteine metabolite I investigated by electron paramagnetic resonance spectroscopy. | 2010 |
|
| Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. | 2010 Apr |
|
| Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. | 2010 Aug |
|
| Effects of sulphurous water on human neutrophil elastase release. | 2010 Dec |
|
| Association between lung function and exacerbation frequency in patients with COPD. | 2010 Dec 9 |
|
| Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. | 2010 Feb 8 |
|
| Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide. | 2010 Jul-Sep |
|
| Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study. | 2010 Jun |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:20:17 GMT 2025
by
admin
on
Mon Mar 31 18:20:17 GMT 2025
|
| Record UNII |
76J0853EKA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
417413
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
||
|
WHO-ATC |
R05CB15
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
||
|
WHO-VATC |
QR05CB15
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
||
|
NCI_THESAURUS |
C74536
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/12/1084
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C61750
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
C048498
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
SUB06595MIG
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL1697744
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
24305
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
1041
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
DTXSID8048735
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
65632
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
m4974
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
84611-23-4
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
ERDOSTEINE
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
DB05057
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
100000084578
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
76J0853EKA
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
6032
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|